Trial results for a Phase 2 study (NCT02446457) investigating pembrolizumab (Keytruda) in combination with rituximab, with or without lenalidomide, for patients with relapsed follicular lymphoma and diffuse large B-cell lymphoma were posted on ClinicalTrials.gov on 2026-02-27. The study reported counts of participants achieving Overall Response Rate (Complete + Partial Responses) across its treatment cohorts.
Background
This Phase 2 trial explored combination therapies for patients with follicular lymphoma and diffuse large B-cell lymphoma that had returned after a period of improvement. The study aimed to evaluate how well rituximab and pembrolizumab, with or without lenalidomide, worked in treating these recurrent lymphomas.
Trial design
The study, NCT02446457, was a Phase 2 trial with an enrollment of 53 participants. It investigated treatment for patients with Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, and Recurrent Grade 3a Follicular Lymphoma. The trial evaluated two main treatment cohorts: Cohort I, which received rituximab and pembrolizumab, and Cohort II, which received rituximab, pembrolizumab, and lenalidomide.
Key results
The trial reported counts of participants achieving an Overall Response Rate (Complete + Partial Responses) for each cohort:
- For Cohort I (Rituximab, Pembrolizumab), the reported counts of participants achieving Overall Response Rate were 15 Participants, 5 Participants, 0 Participants, and 0 Participants.
- For Cohort II (Rituximab, Pembrolizumab, Lenalidomide), the reported counts of participants achieving Overall Response Rate were 5 Participants, 0 Participants, 2 Participants, and 7 Participants.
What this means
The posted trial results provide initial data on the observed counts of participants achieving an Overall Response Rate (Complete + Partial Responses) for the investigated combination therapies in relapsed follicular lymphoma and diffuse large B-cell lymphoma. These counts offer insights into the responses observed within each treatment cohort, informing further research and clinical consideration for these patient populations.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT02446457, titled "Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lym," were posted on 2026-02-27 on clinicaltrials.gov.